Compare Stocks → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACRSNASDAQ:ALPNNASDAQ:TORC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.25-0.8%$1.21$0.59▼$11.12$88.66M0.211.74 million shs109,412 shsALPNAlpine Immune Sciences$38.43-0.6%$31.57$6.71▼$42.88$2.52B1.131.11 million shs50,254 shsTORCresTORbio$2.33+4.0%$12.16$0.86▼$10.50$84.94M2.431.15 million shs614,658 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+6.78%+5.88%+4.13%+17.76%-84.33%ALPNAlpine Immune Sciences+3.20%-3.93%+11.22%+97.60%+435.32%TORCresTORbio+4.02%+14.78%-5.67%+32.39%-60.64%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.9633 of 5 stars3.14.00.00.03.21.71.3ALPNAlpine Immune Sciences1.4836 of 5 stars2.51.00.00.03.84.20.0TORCresTORbioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics2.14Hold$22.251,680.00% UpsideALPNAlpine Immune Sciences3.00Buy$38.861.11% UpsideTORCresTORbioN/AN/AN/AN/ACurrent Analyst RatingsLatest ACRS, TORC, and ALPN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2024ALPNAlpine Immune SciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $47.003/19/2024ALPNAlpine Immune SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$47.003/19/2024ALPNAlpine Immune SciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00 ➝ $44.003/19/2024ALPNAlpine Immune SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $50.002/15/2024ALPNAlpine Immune SciencesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$44.001/26/2024ALPNAlpine Immune SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $35.001/22/2024ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral1/12/2024ACRSAclaris TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral1/11/2024ACRSAclaris TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral12/29/2023ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$31.25M2.84N/AN/A$2.22 per share0.56ALPNAlpine Immune Sciences$58.88M42.78N/AN/A$5.64 per share6.81TORCresTORbioN/AN/AN/AN/A$2.24 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$88.48M-$1.27N/AN/AN/A-283.15%-64.56%-49.10%5/13/2024 (Estimated)ALPNAlpine Immune Sciences-$32.18M-$0.64N/AN/AN/A-54.66%-15.54%-11.34%5/9/2024 (Estimated)TORCresTORbio-$82.74M-$2.41N/AN/AN/AN/A-78.12%-71.63%N/ALatest ACRS, TORC, and ALPN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/2024Q4 2023ACRSAclaris Therapeutics-$0.37-$0.30+$0.07-$0.58$3.96 million$17.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AALPNAlpine Immune SciencesN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.164.16ALPNAlpine Immune SciencesN/A7.867.86TORCresTORbioN/A20.6920.69OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ALPNAlpine Immune Sciences75.17%TORCresTORbio46.19%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.50%ALPNAlpine Immune Sciences42.30%TORCresTORbio11.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics8670.93 million67.02 millionOptionableALPNAlpine Immune Sciences12665.55 million37.82 millionOptionableTORCresTORbioN/A36.45 millionN/ANot OptionableACRS, TORC, and ALPN HeadlinesSourceHeadlineAdicet Bio Inc (ACET)investing.com - January 30 at 1:54 PMTargeting the biology of aging with mTOR inhibitors - Nature.comnews.google.com - May 4 at 10:20 PMPARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid ... - OncLivenews.google.com - March 17 at 7:14 PMMichelle Chaka Joins Torc as Senior Vice President, Safety and Regulatoryfinance.yahoo.com - February 24 at 7:08 PMTorc names regulatory, safety SVPvirginiabusiness.com - February 24 at 7:08 PMGlobal AI in Life Extension Market Poised for Growth Amidst Rising Demand for Prolonging Life (2022 - 2030) - openPRnews.google.com - February 8 at 10:13 AMPhenotypic Presentations and the Management of Moderate to ... - Healionews.google.com - January 31 at 2:37 PMAerovate Therapeutics Appoints Donald Santel To Its Board of ... - Marketscreener.comnews.google.com - January 23 at 3:41 PMAerovate Therapeutics Appoints Donald Santel To Its Board of ... - GlobeNewswirenews.google.com - January 23 at 8:44 AMTinOne Resources Inc. (TORC.V)finance.yahoo.com - January 10 at 8:39 AMresTORbio IPO on Deck, Less than a Year After Licensing Clinical ... - Equities Newsnews.google.com - December 16 at 11:48 PMresTORbio Shows Positive Phase 2b Data in Respiratory Tract Infections - Equities Newsnews.google.com - December 12 at 10:01 PMBrian Kennedy – validating aging interventions and why rapamycin is the gold standard - Longevity.Technologynews.google.com - November 3 at 9:25 PMTORC Investments, LLCgwinnettdailypost.com - October 6 at 9:57 AMCelebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - Forbesforbes.com - September 19 at 2:52 PMFast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times - The Business Journalsbizjournals.com - September 12 at 7:31 PMCellular Immunotherapy Market Study 2022-2030 by Current and Upcoming Trends, Opportunities, Size, Trends and - openPRopenpr.com - September 6 at 7:33 AMFor preventing aging, some decades old drugs? - BioWorld Onlinebioworld.com - July 18 at 10:42 PMForm DEF 14A BiomX Inc. For: Aug 24 - StreetInsider.comstreetinsider.com - July 8 at 2:10 AMTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GuruFocus.comgurufocus.com - June 21 at 9:11 PMThe Best Hand Creams - Don't Waste Your Moneydontwasteyourmoney.com - June 18 at 1:34 PMTime Passages: Bruce Goldsmith out at Jim Wilson's gene therapy biotech; Flagship reveals Michael Severino's CEO gig - Endpoints Newsendpts.com - June 3 at 11:42 PMTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - KULR-TVkulr8.com - June 3 at 11:42 PMTerns Pharmaceuticals Inc. (TERN) Appoints Kerry Russell as Chief Medical Officer - StreetInsider.comstreetinsider.com - June 1 at 9:12 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAclaris TherapeuticsNASDAQ:ACRSAclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Alpine Immune SciencesNASDAQ:ALPNAlpine Immune Sciences, Inc. operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept, a dual B cell cytokine antagonist for multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways for treatment of severe inflammatory diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.resTORbioNASDAQ:TORCAdicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.